NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Surgical and Orthopedic Devices M&A update, 14–28 September 2026

A bi-weekly update on surgical and orthopedic devices covering public market moves, major news catalysts, M&A activity and standing valuation benchmarks for the September 14–28, 2026 window. Built for operators, acquirers and advisors tracking the sector's 24 covered names.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Surgical and Orthopedic Devices Sector Outlook — September 2026

Key figures

Sector median move
-1.7%
24 covered names, close-to-close
S&P 500 return
+0.8%
same window
Intuitive Surgical (ISRG)
+9.8%
two-week move
PROCEPT BioRobotics (PRCT)
-17.9%
two-week move

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › SURGICAL AND ORTHOPEDIC DEVICES

Evidence Earns the Premium While Disclosure Questions Reset Core Names

This update covers what moved in surgical and orthopedic devices over the two-week period of September 14–28, 2026, and what it means for operators, acquirers and advisors.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Surgical and Orthopedic Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Surgical and orthopedic devices traded stock-by-stock over September 14–28, 2026: 14 of 24 covered names fell, with a -1.7% median move against +0.8% for the S&P 500. Intuitive Surgical (ISRG) led at +9.8% on clinical outcomes evidence, while PROCEPT BioRobotics (PRCT) and Apyx Medical (APYX) posted the widest declines amid litigation and disclosure questions. No new transactions were recorded, so the standing EV/Revenue median of 2.3x remains the reference frame for diligence.

Key findings

  • 14 of 24 covered names fell; median move -1.7% vs +0.8% for the S&P 500.
  • ISRG rose +9.8%, linked to a da Vinci outcomes study recorded in the window.
  • PROCEPT BioRobotics (PRCT) fell -17.9% amid shareholder litigation notices in-window.
  • No new precedent deals recorded; standing EV/Revenue median holds at 2.3x.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › SURGICAL AND ORTHOPEDIC DEVICES

    This is the cover for the Surgical and Orthopedic Devices bi-weekly industry events and M&A update covering September 14–28, 2026.

    We open with the two-week record for surgical and orthopedic devices, covering what moved, who moved and most likely why, what transacted, and what it means. This sets up the evidence-versus-disclosure split that defines the period.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › SURGICAL AND ORTHOPEDIC DEVICES Evidence Earns the Premium While Disclosure Questions Reset Core Names This update covers what moved in surgical and orthopedic devices over the two-week period of September 14–28, 2026, and what it means for operators, acquirers and advisors. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Surgical and Orthopedic Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    Clinical Evidence Was Rewarded While Litigation Overhang Weighed on Core Names

    This slide summarizes the two-week period across 24 covered names on a close-to-close basis.

    We start with the headline split: 14 of 24 covered names fell, and the median move was -1.7% against +0.8% for the S&P 500, so this was a stock-by-stock period rather than a sector-wide move. Intuitive Surgical (ISRG) led the group at +9.8%, with clinical outcomes evidence sitting behind its strength. PROCEPT BioRobotics (PRCT) and Apyx Medical (APYX) posted the widest declines, at -17.9% and -17.2%, as litigation and disclosure questions ran through the window. So what: names that carried clinical evidence held up, while open legal and disclosure questions set the discount.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE Clinical Evidence Was Rewarded While Litigation Overhang Weighed on Core Names The two-week period in one page · 24 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Surgical and Orthopedic Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 14 of 24 Covered Names Fell; The Median Move Was -1.7% The S&P 500 returned +0.8% over the same window, so the group as a whole trailed the broad market. 10 of the 24 covered names still finished higher, which makes this a stock-by-stock period rather than a sector move. 2 Robotic Outcomes Evidence Sat Behind the Top of the Group Intuitive Surgical, Inc. (ISRG), a Premium-tier name, gained +9.8%, with its strongest day at +2.6% on Sep 18. Its in-window record includes a da Vinci meta-analysis headline reporting better perioperative outcomes versus laparoscopic and open surgery. 3 The Two Widest Declines Both Landed in the Core Tier PROCEPT BioRobotics Corporation (PRCT) fell -17.9% as shareholder litigation notices ran through the window, and Apyx Medical Corporation (APYX) fell -17.2%, including a -15.5% day on Sep 28. 4 The Transaction Record Stood Still, so the Standing Valuation Frame Holds No new transactions were recorded in the window. NeuraCap's standing sector lens still anchors on EV / Revenue at a 2.3x median, with the Premium tier at 6.6x and the Discount tier at 1.0x. +13.7% Best mover — ClearPoint Neuro, Inc. (CLPT) worst: PRCT -17.9% · 10 up / 14 down of 24 covered -1.7% Sector median two-week return vs S&P 500 +0.8%

  3. 03
    PUBLIC MARKET MOVERS

    What the Two-Week Period Paid for, and What It Marked Down

    This slide details which covered names gained and which fell over the two-week window, close-to-close.

    We size each move against a sector median of -1.7% and a materiality bar of ±8.4% on a sector-relative basis, so clients can see which moves are noise and which are signal. Intuitive Surgical (ISRG) cleared that bar to the upside at +9.8%, while PROCEPT BioRobotics (PRCT) and Apyx Medical (APYX) cleared it to the downside at -17.9% and -17.2%. We link every move only to filings and headlines recorded in the window, and where no driver is recorded, we say so plainly. So what: the moves that cleared the bar are the ones worth diligence time this period.

    Everything on this page

    PUBLIC MARKET MOVERS What the Two-Week Period Paid for, and What It Marked Down Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -1.7% · S&P 500 +0.8% · materiality bar ±8.4% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Surgical and Orthopedic Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -1.7% PROCEPT BioRobotics Corporation (PRCT) -17.9% Shares moved following the securities class action notices dated Sep 14, which allege that offering-period disclosures omitted a discount-driven handpiece ordering program and excess field inventory risk. Pull-through claims get tested hard when field inventory is the open question. COMPANY-SPECIFIC Intuitive Surgical, Inc. (ISRG) +9.8% The move appears consistent with the in-window da Vinci meta-analysis headline of Sep 15, which reported better perioperative outcomes versus laparoscopic and open surgery, alongside coverage of the company's AI and instrument roadmap. Registry-scale evidence still supports Premium-tier pricing for enabling technology. COMPANY-SPECIFIC Establishment Labs Holdings Inc. (ESTA) -9.1% Shares fell -9.1% even as Establishment Labs Holdings Inc. (ESTA) presented new breast tissue preservation data and announced minimally invasive product extensions on Sep 21. New data alone does not carry a Premium-tier name without procedure adoption behind it. COMPANY-SPECIFIC Apyx Medical Corporation (APYX) -17.2% No notable in-window news was identified that clearly explains the move. The -17.2% decline sits far below the sector median move of -1.7%. Smaller Core-tier names swing widely when the period's record is quiet. UNEXPLAINED

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    One Company's Disclosure Question Carried the Period's News Record

    This slide lists the two-week period's highest-impact news events, each linked to its underlying filing or article.

    We lead with the period's single highest-impact story: a disclosure question at one covered name that carried the news record for the window. Each event on this page links back to its source, and our 'why it matters' read is a NeuraCap interpretation of the recorded evidence rather than a restatement of it. Sources follow a fixed reliability order — SEC filings first, then press releases, then established outlets. So what: this is the story clients should be able to speak to before their next conversation with this name.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS One Company's Disclosure Question Carried the Period's News Record The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Surgical and Orthopedic Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 15 · NEWS · GlobeNewsWire PROCEPT BioRobotics drawn into a securities class action over offering-period disclosures The allegations center on a discount-driven handpiece ordering program and excess field inventory risk. Those are the exact mechanics that decide whether pull-through behind a placed system is genuinely recurring. Buyers will read handpiece pull-through against field inventory before they trust the razorblade. Sep 15 · NEWS · PRNewsWire Investor notice cites repeated handpiece sales underperformance at PROCEPT BioRobotics Recurring handpiece revenue is the engine of razor-and-razorblade economics in this group. Questions about its consistency go straight to revenue quality rather than to any one quarter. Utilization of placed systems, not placement counts, is what carries the multiple. Sep 15 · NEWS · GlobeNewsWire Lead plaintiff deadline set in the PROCEPT BioRobotics securities case A fixed procedural deadline kept the disclosure question in front of investors for most of the window, and it sat alongside the period's widest decline in the covered set. A disclosure overhang can compress a Core-tier multiple faster than operating results move it. Sep 15 · NEWS · GlobeNewsWire Class action filed covering PROCEPT BioRobotics purchases across a defined class period The claim spans a multi-quarter stretch of reported results, which widens the question from a single print to a full commercial cycle of ordering behavior. Multi-period claims put sales territory productivity and ordering incentives under review. Sep 15 · NEWS · Newsfile Corp Additional notice issued to PROCEPT BioRobotics purchasers ahead of the litigation deadline NeuraCap's read: the number of separate notices inside a single window signals the claim is being actively pursued, which tends to keep the disclosure question live for longer. Litigation news flow can hold the story while the operating base keeps running. Sep 14 · NEWS · GlobeNewsWire Shareholder notice landed at the opening of the window for PROCEPT BioRobotics The litigation record was already public at the start of the period, which frames how the rest of the company's news in the window was received. The sequence of disclosure and price action is what acquirers reconstruct in diligence.

  5. 05
    M&A & STRATEGIC ACTIVITY

    The Reference Set Stayed Put While the Story Moved to Disclosure

    This slide reviews the two-week period's M&A and strategic activity against a precedent set of 40 recorded deals.

    No new transactions were recorded in this window, so the story this period moved from deal-making to disclosure. That leaves the standing precedent set — 40 recorded deals — as the still-current reference for valuation work, with deal multiples read as LTM at announcement where disclosed. We don't re-present old transactions as news, so this page stays quiet by design. So what: the valuation frame acquirers should use this period is the same one they used last period.

    Everything on this page

    M&A & STRATEGIC ACTIVITY The Reference Set Stayed Put While the Story Moved to Disclosure September 14–28, 2026 · precedent transactions: 40 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Surgical and Orthopedic Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The trailing record still carries 40 precedent transactions as the reference set, with nothing added in this window. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 40 Recorded precedent transactions the reference set buyers and sellers price against

  6. 06
    WHAT IT MEANS

    What This Two-Week Period Changes for Operators, Buyers and Advisors

    This slide translates the two-week period's evidence into observations for operators, acquirers and advisors.

    For owners and operators, utilization and clinical pull-through are what the period paid for, and the names that held up carried evidence behind the procedure. For acquirers, nothing new was added to the precedent record, so the standing EV/Revenue frame holds — a 2.3x median, with the Premium tier at 6.6x and the Discount tier at 1.0x. For advisors, the period's split is the story to lead with: 14 of 24 covered names fell, at a -1.7% median, against +0.8% for the S&P 500. So what: these are observations to bring into client conversations, not recommendations.

    Everything on this page

    WHAT IT MEANS What This Two-Week Period Changes for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Surgical and Orthopedic Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 2.3x 27 companies in the study 3 valuation tiers Standing thesis: Surgical and Orthopedic Devices Split Across Four Models, with Growth and Instruments Priced Higher FOR OWNERS & OPERATORS Utilization and Pull-Through Are What the Period Paid For Companies in the sector traded in both directions, and the names that held up carried clinical evidence behind the procedure. FOR ACQUIRERS No New Records, but a Sharper Diligence Checklist Nothing was added to the precedent record this period, so the standing frame holds: an EV / Revenue median of 2.3x, with the Premium tier at 6.6x and the Discount tier at 1.0x. FOR ADVISORS Lead with the Split the Period Drew Evidence supported the top of the group while an open disclosure question sat on a Core-tier name. 14 of 24 covered names fell; the median move was -1.7%, against +0.8% for the S&P 500.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    This slide explains the sources and methodology behind the update and states the important notice.

    Every figure in this update links to the record it was taken from, and the publishers and filings we drew on for the period are listed on this page. We hold driver attributions to calibrated language throughout, distinguishing what the filings and headlines show from our own read of why it happened. So what: clients can trace any number in this deck back to its source before they act on it.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Surgical and Orthopedic Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 3 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T154543Z_520_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: globenewswire.com · prnewswire.com · newsfilecorp.com

Sources and methodology

This update covers Surgical and Orthopedic Devices over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 24 listed companies whose core business is Surgical and Orthopedic Devices under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Apyx Medical Corporation (APYX), Alphatec Holdings, Inc. (ATEC), AxoGen, Inc. (AXGN), Bioventus Inc. (BVS), Carlsmed, Inc. (CARL), ClearPoint Neuro, Inc. (CLPT), CONMED Corporation (CNMD), Establishment Labs Holdings Inc. (ESTA), Globus Medical, Inc. (GMED), Integra LifeSciences Holdings Corporation (IART), Inspire Medical Systems, Inc. (INSP), Intuitive Surgical, Inc. (ISRG), OrthoPediatrics Corp. (KIDS), Orthofix Medical Inc. (OFIX), Pro-Dex, Inc. (PDEX), PROCEPT BioRobotics Corporation (PRCT), Shoulder Innovations, Inc. (SI), SI-BONE, Inc. (SIBN), Smith & Nephew plc (SNN), SS Innovations International, Inc. (SSII), Stryker Corporation (SYK), Treace Medical Concepts, Inc. (TMCI), Utah Medical Products, Inc. (UTMD), Zimmer Biomet Holdings, Inc. (ZBH). 3 names below the floor were excluded from the statistics: ARAY, LNSR, MBOT.

Window and company universe

This update covers Surgical and Orthopedic Devices over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 24 listed companies whose core business is Surgical and Orthopedic Devices under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Apyx Medical Corporation (APYX), Alphatec Holdings, Inc. (ATEC), AxoGen, Inc. (AXGN), Bioventus Inc. (BVS), Carlsmed, Inc. (CARL), ClearPoint Neuro, Inc. (CLPT), CONMED Corporation (CNMD), Establishment Labs Holdings Inc. (ESTA), Globus Medical, Inc. (GMED), Integra LifeSciences Holdings Corporation (IART), Inspire Medical Systems, Inc. (INSP), Intuitive Surgical, Inc. (ISRG), OrthoPediatrics Corp. (KIDS), Orthofix Medical Inc. (OFIX), Pro-Dex, Inc. (PDEX), PROCEPT BioRobotics Corporation (PRCT), Shoulder Innovations, Inc. (SI), SI-BONE, Inc. (SIBN), Smith & Nephew plc (SNN), SS Innovations International, Inc. (SSII), Stryker Corporation (SYK), Treace Medical Concepts, Inc. (TMCI), Utah Medical Products, Inc. (UTMD), Zimmer Biomet Holdings, Inc. (ZBH). 3 names below the floor were excluded from the statistics: ARAY, LNSR, MBOT.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Surgical and Orthopedic Devices?

Company valuation reports run the same method against a single business — public or private.